Baseline characteristics of study population (n=176)
| Clinical characteristic | Value |
|---|---|
| Age (years) | 30.7±6.9 |
| Parity, n (range) | 2 (1–7) |
| BMI (kg/cm2) | 25.6±5.2 |
| Systolic blood pressure (mm Hg) | 111±17 |
| Diastolic blood pressure (mm Hg) | 72±13 |
| Heart rate (beats/min) | 97.3±19.1 |
| NYHA functional class, n (%) | |
| I/II | 33 (18) |
| III/IV | 143 (82) |
| Echocardiography | |
| LVEDD (mm) | 59.5±7.3 |
| LVESD (mm) | 51.8±7.6 |
| Ejection fraction (%) | 27.1±8.1 |
| E velocity (m/s) | 0.89±0.25 |
| A velocity (m/s) | 0.49±0.20 |
| E/A | 2.02±0.89 |
| Deceleration time (ms) | 134.5±63.2 |
| LV thrombus, n (%) | 19 (11.1) |
| Laboratory | |
| Haemoglobin (g/dl) | 12.1±1.8 |
| Creatinine (mmol/l) | 84.1±20.5 |
| Urea (mmol/l) | 5.4±2.9 |
| Total protein (g/l) | 77.9±11.4 |
| Albumin (g/l) | 40.1±18.5 |
| Total bilirubin (μmol/l) | 17.3±26.8 |
| Direct bilirubin (μmol/l) | 9.2±23.2 |
| Indirect bilirubin (μmol/l) | 8.2±7.3 |
| Alkaline phosphatase (U/l) | 117.9±51.0 |
| AST (U/l) | 45.0±46.8 |
| ALT (U/l) | 54.7±67.1 |
| GGT (U/l) | 72.4±49.4 |
| Total cholesterol (mmol/l) | 4.0±1.1 |
Values are mean±SD unless otherwise specified.
ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; GGT, γ-glutamyl transpeptidase; LV, left ventricular; LVEDD, LV end diastolic diameter; LVESD, LV end systolic diameter; NYHA, New York Heart Association.